nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—HTR7—vein—ovarian cancer	0.0213	0.106	CbGeAlD
Mianserin—HTR2A—vein—ovarian cancer	0.0133	0.0659	CbGeAlD
Mianserin—HRH4—bone marrow—ovarian cancer	0.0108	0.0536	CbGeAlD
Mianserin—CYP2D6—Vinorelbine—ovarian cancer	0.00589	0.212	CbGbCtD
Mianserin—CYP3A4—Topotecan—ovarian cancer	0.00531	0.192	CbGbCtD
Mianserin—HTR2B—myometrium—ovarian cancer	0.00489	0.0243	CbGeAlD
Mianserin—OPRK1—female reproductive system—ovarian cancer	0.00486	0.0241	CbGeAlD
Mianserin—CYP2B6—Doxorubicin—ovarian cancer	0.00461	0.166	CbGbCtD
Mianserin—ADRA2C—myometrium—ovarian cancer	0.00385	0.0191	CbGeAlD
Mianserin—HTR2B—uterine cervix—ovarian cancer	0.00381	0.0189	CbGeAlD
Mianserin—CYP3A4—Vinorelbine—ovarian cancer	0.00374	0.135	CbGbCtD
Mianserin—HTR2B—decidua—ovarian cancer	0.00363	0.018	CbGeAlD
Mianserin—HTR2B—endometrium—ovarian cancer	0.00344	0.0171	CbGeAlD
Mianserin—HTR7—epithelium—ovarian cancer	0.00329	0.0163	CbGeAlD
Mianserin—SLC6A2—decidua—ovarian cancer	0.00322	0.016	CbGeAlD
Mianserin—HTR2B—uterus—ovarian cancer	0.00317	0.0157	CbGeAlD
Mianserin—HRH1—myometrium—ovarian cancer	0.00313	0.0155	CbGeAlD
Mianserin—ADRA2A—myometrium—ovarian cancer	0.00307	0.0152	CbGeAlD
Mianserin—HTR1D—female reproductive system—ovarian cancer	0.00306	0.0152	CbGeAlD
Mianserin—HTR2C—female reproductive system—ovarian cancer	0.00304	0.0151	CbGeAlD
Mianserin—ADRA2C—uterine cervix—ovarian cancer	0.003	0.0149	CbGeAlD
Mianserin—SLC6A4—female reproductive system—ovarian cancer	0.00288	0.0143	CbGeAlD
Mianserin—ADRA2C—decidua—ovarian cancer	0.00285	0.0142	CbGeAlD
Mianserin—HTR2B—female reproductive system—ovarian cancer	0.00285	0.0142	CbGeAlD
Mianserin—SLC6A2—gonad—ovarian cancer	0.00284	0.0141	CbGeAlD
Mianserin—HRH2—lymph node—ovarian cancer	0.00281	0.0139	CbGeAlD
Mianserin—HTR7—gonad—ovarian cancer	0.00273	0.0136	CbGeAlD
Mianserin—ADRA2C—endometrium—ovarian cancer	0.00271	0.0134	CbGeAlD
Mianserin—CYP3A4—Paclitaxel—ovarian cancer	0.00263	0.0948	CbGbCtD
Mianserin—HTR2B—vagina—ovarian cancer	0.00258	0.0128	CbGeAlD
Mianserin—SLC6A3—testis—ovarian cancer	0.00253	0.0126	CbGeAlD
Mianserin—SLC6A2—female reproductive system—ovarian cancer	0.00253	0.0126	CbGeAlD
Mianserin—HTR2A—embryo—ovarian cancer	0.00251	0.0125	CbGeAlD
Mianserin—ADRA2C—uterus—ovarian cancer	0.0025	0.0124	CbGeAlD
Mianserin—HRH1—epithelium—ovarian cancer	0.00245	0.0122	CbGeAlD
Mianserin—HTR7—female reproductive system—ovarian cancer	0.00244	0.0121	CbGeAlD
Mianserin—HRH1—uterine cervix—ovarian cancer	0.00243	0.0121	CbGeAlD
Mianserin—ADRA2A—uterine cervix—ovarian cancer	0.00239	0.0119	CbGeAlD
Mianserin—HRH1—decidua—ovarian cancer	0.00232	0.0115	CbGeAlD
Mianserin—ADRA2A—decidua—ovarian cancer	0.00228	0.0113	CbGeAlD
Mianserin—Thrombocytopenia—Melphalan—ovarian cancer	0.00226	0.00377	CcSEcCtD
Mianserin—Tachycardia—Melphalan—ovarian cancer	0.00226	0.00376	CcSEcCtD
Mianserin—Skin disorder—Melphalan—ovarian cancer	0.00224	0.00374	CcSEcCtD
Mianserin—Neutropenia—Paclitaxel—ovarian cancer	0.00223	0.00372	CcSEcCtD
Mianserin—CYP2D6—Doxorubicin—ovarian cancer	0.00223	0.0804	CbGbCtD
Mianserin—Vertigo—Vinorelbine—ovarian cancer	0.00222	0.00371	CcSEcCtD
Mianserin—Leukopenia—Vinorelbine—ovarian cancer	0.00221	0.00369	CcSEcCtD
Mianserin—HRH1—endometrium—ovarian cancer	0.0022	0.0109	CbGeAlD
Mianserin—Feeling abnormal—Chlorambucil—ovarian cancer	0.00218	0.00364	CcSEcCtD
Mianserin—Weight increased—Paclitaxel—ovarian cancer	0.00217	0.00362	CcSEcCtD
Mianserin—ADRA2A—endometrium—ovarian cancer	0.00216	0.0107	CbGeAlD
Mianserin—Hypotension—Melphalan—ovarian cancer	0.00216	0.0036	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00215	0.00359	CcSEcCtD
Mianserin—Hypertension—Vinorelbine—ovarian cancer	0.00214	0.00356	CcSEcCtD
Mianserin—Paraesthesia—Topotecan—ovarian cancer	0.00212	0.00353	CcSEcCtD
Mianserin—Breast disorder—Docetaxel—ovarian cancer	0.00212	0.00353	CcSEcCtD
Mianserin—Arthralgia—Vinorelbine—ovarian cancer	0.00211	0.00351	CcSEcCtD
Mianserin—Myalgia—Vinorelbine—ovarian cancer	0.00211	0.00351	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00211	0.00351	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00209	0.00349	CcSEcCtD
Mianserin—CYP2B6—gonad—ovarian cancer	0.00209	0.0104	CbGeAlD
Mianserin—Paraesthesia—Melphalan—ovarian cancer	0.00208	0.00346	CcSEcCtD
Mianserin—HTR2A—epithelium—ovarian cancer	0.00205	0.0102	CbGeAlD
Mianserin—SLC6A2—testis—ovarian cancer	0.00204	0.0102	CbGeAlD
Mianserin—ADRA2C—female gonad—ovarian cancer	0.00204	0.0101	CbGeAlD
Mianserin—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00204	0.0034	CcSEcCtD
Mianserin—Fatigue—Topotecan—ovarian cancer	0.00204	0.00339	CcSEcCtD
Mianserin—ADRA2C—vagina—ovarian cancer	0.00203	0.0101	CbGeAlD
Mianserin—Constipation—Topotecan—ovarian cancer	0.00202	0.00337	CcSEcCtD
Mianserin—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.00201	0.00336	CcSEcCtD
Mianserin—ADRA2A—gonad—ovarian cancer	0.002	0.00995	CbGeAlD
Mianserin—Gastrointestinal disorder—Melphalan—ovarian cancer	0.002	0.00333	CcSEcCtD
Mianserin—Fatigue—Melphalan—ovarian cancer	0.00199	0.00332	CcSEcCtD
Mianserin—ADRA2A—uterus—ovarian cancer	0.00199	0.00989	CbGeAlD
Mianserin—Nervous system disorder—Vinorelbine—ovarian cancer	0.00198	0.0033	CcSEcCtD
Mianserin—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00198	0.0033	CcSEcCtD
Mianserin—Tachycardia—Vinorelbine—ovarian cancer	0.00197	0.00329	CcSEcCtD
Mianserin—HTR7—testis—ovarian cancer	0.00197	0.00978	CbGeAlD
Mianserin—Skin disorder—Vinorelbine—ovarian cancer	0.00196	0.00327	CcSEcCtD
Mianserin—Bradycardia—Paclitaxel—ovarian cancer	0.00195	0.00325	CcSEcCtD
Mianserin—Feeling abnormal—Topotecan—ovarian cancer	0.00195	0.00324	CcSEcCtD
Mianserin—Pancytopenia—Docetaxel—ovarian cancer	0.00192	0.00321	CcSEcCtD
Mianserin—Asthenia—Chlorambucil—ovarian cancer	0.0019	0.00317	CcSEcCtD
Mianserin—CYP3A4—Docetaxel—ovarian cancer	0.0019	0.0685	CbGbCtD
Mianserin—Neutropenia—Docetaxel—ovarian cancer	0.00189	0.00316	CcSEcCtD
Mianserin—Hypotension—Vinorelbine—ovarian cancer	0.00189	0.00315	CcSEcCtD
Mianserin—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00188	0.00313	CcSEcCtD
Mianserin—Pruritus—Chlorambucil—ovarian cancer	0.00188	0.00313	CcSEcCtD
Mianserin—CYP2B6—female reproductive system—ovarian cancer	0.00187	0.00927	CbGeAlD
Mianserin—DRD2—testis—ovarian cancer	0.00186	0.00925	CbGeAlD
Mianserin—Weight increased—Docetaxel—ovarian cancer	0.00184	0.00307	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00184	0.00307	CcSEcCtD
Mianserin—HRH1—female reproductive system—ovarian cancer	0.00182	0.00905	CbGeAlD
Mianserin—Paraesthesia—Vinorelbine—ovarian cancer	0.00181	0.00302	CcSEcCtD
Mianserin—ADRA2C—testis—ovarian cancer	0.00181	0.00899	CbGeAlD
Mianserin—Hepatic function abnormal—Epirubicin—ovarian cancer	0.00181	0.00301	CcSEcCtD
Mianserin—ADRA2A—female reproductive system—ovarian cancer	0.00179	0.00889	CbGeAlD
Mianserin—Eye disorder—Paclitaxel—ovarian cancer	0.00179	0.00298	CcSEcCtD
Mianserin—Tinnitus—Paclitaxel—ovarian cancer	0.00178	0.00297	CcSEcCtD
Mianserin—Cardiac disorder—Paclitaxel—ovarian cancer	0.00177	0.00296	CcSEcCtD
Mianserin—Jaundice—Docetaxel—ovarian cancer	0.00176	0.00293	CcSEcCtD
Mianserin—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00174	0.00291	CcSEcCtD
Mianserin—Fatigue—Vinorelbine—ovarian cancer	0.00174	0.0029	CcSEcCtD
Mianserin—Angiopathy—Paclitaxel—ovarian cancer	0.00173	0.00289	CcSEcCtD
Mianserin—Constipation—Vinorelbine—ovarian cancer	0.00173	0.00288	CcSEcCtD
Mianserin—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00172	0.00287	CcSEcCtD
Mianserin—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00171	0.00285	CcSEcCtD
Mianserin—HTR2A—gonad—ovarian cancer	0.0017	0.00846	CbGeAlD
Mianserin—Asthenia—Topotecan—ovarian cancer	0.00169	0.00282	CcSEcCtD
Mianserin—CYP2B6—vagina—ovarian cancer	0.00169	0.00838	CbGeAlD
Mianserin—Agranulocytosis—Docetaxel—ovarian cancer	0.00168	0.00281	CcSEcCtD
Mianserin—Mental disorder—Paclitaxel—ovarian cancer	0.00167	0.00279	CcSEcCtD
Mianserin—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.00167	0.00279	CcSEcCtD
Mianserin—Pruritus—Topotecan—ovarian cancer	0.00167	0.00278	CcSEcCtD
Mianserin—HTR2B—lymph node—ovarian cancer	0.00167	0.00828	CbGeAlD
Mianserin—Feeling abnormal—Vinorelbine—ovarian cancer	0.00166	0.00277	CcSEcCtD
Mianserin—HRH1—female gonad—ovarian cancer	0.00166	0.00824	CbGeAlD
Mianserin—Asthenia—Melphalan—ovarian cancer	0.00166	0.00277	CcSEcCtD
Mianserin—HRH1—vagina—ovarian cancer	0.00165	0.00819	CbGeAlD
Mianserin—Pruritus—Melphalan—ovarian cancer	0.00164	0.00273	CcSEcCtD
Mianserin—ADRA2A—female gonad—ovarian cancer	0.00163	0.00809	CbGeAlD
Mianserin—Hepatitis—Docetaxel—ovarian cancer	0.00162	0.0027	CcSEcCtD
Mianserin—ADRA2A—vagina—ovarian cancer	0.00162	0.00804	CbGeAlD
Mianserin—Cardiac failure—Epirubicin—ovarian cancer	0.00162	0.0027	CcSEcCtD
Mianserin—Lethargy—Epirubicin—ovarian cancer	0.00161	0.00269	CcSEcCtD
Mianserin—Connective tissue disorder—Docetaxel—ovarian cancer	0.00159	0.00266	CcSEcCtD
Mianserin—Diplopia—Epirubicin—ovarian cancer	0.00158	0.00263	CcSEcCtD
Mianserin—Dizziness—Topotecan—ovarian cancer	0.00156	0.0026	CcSEcCtD
Mianserin—Tremor—Paclitaxel—ovarian cancer	0.00156	0.0026	CcSEcCtD
Mianserin—Anaemia—Paclitaxel—ovarian cancer	0.00154	0.00256	CcSEcCtD
Mianserin—Agitation—Paclitaxel—ovarian cancer	0.00153	0.00255	CcSEcCtD
Mianserin—HTR2A—female reproductive system—ovarian cancer	0.00152	0.00756	CbGeAlD
Mianserin—Eye disorder—Docetaxel—ovarian cancer	0.00151	0.00253	CcSEcCtD
Mianserin—CYP2B6—testis—ovarian cancer	0.00151	0.00748	CbGeAlD
Mianserin—Cardiac disorder—Docetaxel—ovarian cancer	0.0015	0.00251	CcSEcCtD
Mianserin—Cardiac arrest—Epirubicin—ovarian cancer	0.0015	0.00251	CcSEcCtD
Mianserin—Cardiac failure—Doxorubicin—ovarian cancer	0.0015	0.0025	CcSEcCtD
Mianserin—Vertigo—Paclitaxel—ovarian cancer	0.0015	0.00249	CcSEcCtD
Mianserin—Syncope—Paclitaxel—ovarian cancer	0.00149	0.00249	CcSEcCtD
Mianserin—Lethargy—Doxorubicin—ovarian cancer	0.00149	0.00249	CcSEcCtD
Mianserin—Leukopenia—Paclitaxel—ovarian cancer	0.00149	0.00248	CcSEcCtD
Mianserin—Rash—Topotecan—ovarian cancer	0.00149	0.00248	CcSEcCtD
Mianserin—Dermatitis—Topotecan—ovarian cancer	0.00149	0.00248	CcSEcCtD
Mianserin—SLC6A2—lymph node—ovarian cancer	0.00148	0.00736	CbGeAlD
Mianserin—Headache—Topotecan—ovarian cancer	0.00148	0.00247	CcSEcCtD
Mianserin—HRH1—testis—ovarian cancer	0.00147	0.0073	CbGeAlD
Mianserin—Angiopathy—Docetaxel—ovarian cancer	0.00147	0.00245	CcSEcCtD
Mianserin—Loss of consciousness—Paclitaxel—ovarian cancer	0.00146	0.00244	CcSEcCtD
Mianserin—Diplopia—Doxorubicin—ovarian cancer	0.00146	0.00244	CcSEcCtD
Mianserin—Mediastinal disorder—Docetaxel—ovarian cancer	0.00146	0.00244	CcSEcCtD
Mianserin—Rash—Melphalan—ovarian cancer	0.00146	0.00243	CcSEcCtD
Mianserin—Dermatitis—Melphalan—ovarian cancer	0.00146	0.00243	CcSEcCtD
Mianserin—Asthenia—Vinorelbine—ovarian cancer	0.00145	0.00242	CcSEcCtD
Mianserin—ADRA2A—testis—ovarian cancer	0.00145	0.00717	CbGeAlD
Mianserin—Convulsion—Paclitaxel—ovarian cancer	0.00144	0.0024	CcSEcCtD
Mianserin—Hypertension—Paclitaxel—ovarian cancer	0.00144	0.0024	CcSEcCtD
Mianserin—Pruritus—Vinorelbine—ovarian cancer	0.00143	0.00238	CcSEcCtD
Mianserin—Breast disorder—Epirubicin—ovarian cancer	0.00143	0.00238	CcSEcCtD
Mianserin—Mental disorder—Docetaxel—ovarian cancer	0.00142	0.00237	CcSEcCtD
Mianserin—CYP3A4—Doxorubicin—ovarian cancer	0.00142	0.0511	CbGbCtD
Mianserin—Myalgia—Paclitaxel—ovarian cancer	0.00142	0.00236	CcSEcCtD
Mianserin—Arthralgia—Paclitaxel—ovarian cancer	0.00142	0.00236	CcSEcCtD
Mianserin—CYP3A4—female reproductive system—ovarian cancer	0.00141	0.007	CbGeAlD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00141	0.00235	CcSEcCtD
Mianserin—Cardiac arrest—Doxorubicin—ovarian cancer	0.00139	0.00232	CcSEcCtD
Mianserin—CYP2D6—female reproductive system—ovarian cancer	0.00139	0.00689	CbGeAlD
Mianserin—Dry mouth—Paclitaxel—ovarian cancer	0.00139	0.00231	CcSEcCtD
Mianserin—HTR2A—vagina—ovarian cancer	0.00138	0.00684	CbGeAlD
Mianserin—Confusional state—Paclitaxel—ovarian cancer	0.00137	0.00228	CcSEcCtD
Mianserin—Oedema—Paclitaxel—ovarian cancer	0.00136	0.00226	CcSEcCtD
Mianserin—Shock—Paclitaxel—ovarian cancer	0.00134	0.00223	CcSEcCtD
Mianserin—Dizziness—Vinorelbine—ovarian cancer	0.00134	0.00223	CcSEcCtD
Mianserin—Nervous system disorder—Paclitaxel—ovarian cancer	0.00133	0.00222	CcSEcCtD
Mianserin—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00133	0.00222	CcSEcCtD
Mianserin—Tachycardia—Paclitaxel—ovarian cancer	0.00133	0.00221	CcSEcCtD
Mianserin—Breast disorder—Doxorubicin—ovarian cancer	0.00132	0.0022	CcSEcCtD
Mianserin—Skin disorder—Paclitaxel—ovarian cancer	0.00132	0.0022	CcSEcCtD
Mianserin—ADRA2C—lymph node—ovarian cancer	0.00131	0.00652	CbGeAlD
Mianserin—Anaemia—Docetaxel—ovarian cancer	0.0013	0.00217	CcSEcCtD
Mianserin—Pancytopenia—Epirubicin—ovarian cancer	0.0013	0.00216	CcSEcCtD
Mianserin—Neutropenia—Epirubicin—ovarian cancer	0.00128	0.00213	CcSEcCtD
Mianserin—Rash—Vinorelbine—ovarian cancer	0.00127	0.00212	CcSEcCtD
Mianserin—Dermatitis—Vinorelbine—ovarian cancer	0.00127	0.00212	CcSEcCtD
Mianserin—Hypotension—Paclitaxel—ovarian cancer	0.00127	0.00212	CcSEcCtD
Mianserin—Headache—Vinorelbine—ovarian cancer	0.00126	0.00211	CcSEcCtD
Mianserin—Syncope—Docetaxel—ovarian cancer	0.00126	0.00211	CcSEcCtD
Mianserin—Leukopenia—Docetaxel—ovarian cancer	0.00126	0.00211	CcSEcCtD
Mianserin—CYP2D6—female gonad—ovarian cancer	0.00126	0.00627	CbGeAlD
Mianserin—Weight increased—Epirubicin—ovarian cancer	0.00124	0.00207	CcSEcCtD
Mianserin—Loss of consciousness—Docetaxel—ovarian cancer	0.00124	0.00207	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00124	0.00206	CcSEcCtD
Mianserin—HTR2A—testis—ovarian cancer	0.00123	0.0061	CbGeAlD
Mianserin—Convulsion—Docetaxel—ovarian cancer	0.00122	0.00204	CcSEcCtD
Mianserin—Paraesthesia—Paclitaxel—ovarian cancer	0.00122	0.00203	CcSEcCtD
Mianserin—Hypertension—Docetaxel—ovarian cancer	0.00122	0.00203	CcSEcCtD
Mianserin—Drowsiness—Epirubicin—ovarian cancer	0.00122	0.00203	CcSEcCtD
Mianserin—Somnolence—Paclitaxel—ovarian cancer	0.00121	0.00201	CcSEcCtD
Mianserin—Arthralgia—Docetaxel—ovarian cancer	0.0012	0.002	CcSEcCtD
Mianserin—Myalgia—Docetaxel—ovarian cancer	0.0012	0.002	CcSEcCtD
Mianserin—Pancytopenia—Doxorubicin—ovarian cancer	0.0012	0.002	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00119	0.00199	CcSEcCtD
Mianserin—Jaundice—Epirubicin—ovarian cancer	0.00119	0.00198	CcSEcCtD
Mianserin—Neutropenia—Doxorubicin—ovarian cancer	0.00118	0.00197	CcSEcCtD
Mianserin—Dry mouth—Docetaxel—ovarian cancer	0.00117	0.00196	CcSEcCtD
Mianserin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00117	0.00196	CcSEcCtD
Mianserin—Fatigue—Paclitaxel—ovarian cancer	0.00117	0.00195	CcSEcCtD
Mianserin—Constipation—Paclitaxel—ovarian cancer	0.00116	0.00194	CcSEcCtD
Mianserin—Confusional state—Docetaxel—ovarian cancer	0.00116	0.00194	CcSEcCtD
Mianserin—Hepatobiliary disease—Epirubicin—ovarian cancer	0.00115	0.00192	CcSEcCtD
Mianserin—Oedema—Docetaxel—ovarian cancer	0.00115	0.00192	CcSEcCtD
Mianserin—Weight increased—Doxorubicin—ovarian cancer	0.00115	0.00192	CcSEcCtD
Mianserin—Agranulocytosis—Epirubicin—ovarian cancer	0.00114	0.00189	CcSEcCtD
Mianserin—Shock—Docetaxel—ovarian cancer	0.00113	0.00189	CcSEcCtD
Mianserin—Nervous system disorder—Docetaxel—ovarian cancer	0.00113	0.00188	CcSEcCtD
Mianserin—Thrombocytopenia—Docetaxel—ovarian cancer	0.00113	0.00188	CcSEcCtD
Mianserin—Drowsiness—Doxorubicin—ovarian cancer	0.00113	0.00188	CcSEcCtD
Mianserin—Tachycardia—Docetaxel—ovarian cancer	0.00112	0.00187	CcSEcCtD
Mianserin—CYP2D6—testis—ovarian cancer	0.00112	0.00556	CbGeAlD
Mianserin—Feeling abnormal—Paclitaxel—ovarian cancer	0.00112	0.00187	CcSEcCtD
Mianserin—Skin disorder—Docetaxel—ovarian cancer	0.00112	0.00186	CcSEcCtD
Mianserin—Bradycardia—Epirubicin—ovarian cancer	0.00111	0.00186	CcSEcCtD
Mianserin—Jaundice—Doxorubicin—ovarian cancer	0.0011	0.00183	CcSEcCtD
Mianserin—Hepatitis—Epirubicin—ovarian cancer	0.00109	0.00182	CcSEcCtD
Mianserin—Hypotension—Docetaxel—ovarian cancer	0.00108	0.00179	CcSEcCtD
Mianserin—Connective tissue disorder—Epirubicin—ovarian cancer	0.00107	0.00179	CcSEcCtD
Mianserin—HRH1—lymph node—ovarian cancer	0.00107	0.00529	CbGeAlD
Mianserin—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.00107	0.00178	CcSEcCtD
Mianserin—Agranulocytosis—Doxorubicin—ovarian cancer	0.00105	0.00175	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00105	0.00175	CcSEcCtD
Mianserin—ADRA2A—lymph node—ovarian cancer	0.00105	0.0052	CbGeAlD
Mianserin—Paraesthesia—Docetaxel—ovarian cancer	0.00103	0.00172	CcSEcCtD
Mianserin—Bradycardia—Doxorubicin—ovarian cancer	0.00103	0.00172	CcSEcCtD
Mianserin—Somnolence—Docetaxel—ovarian cancer	0.00102	0.00171	CcSEcCtD
Mianserin—Eye disorder—Epirubicin—ovarian cancer	0.00102	0.0017	CcSEcCtD
Mianserin—Tinnitus—Epirubicin—ovarian cancer	0.00102	0.0017	CcSEcCtD
Mianserin—Cardiac disorder—Epirubicin—ovarian cancer	0.00101	0.00169	CcSEcCtD
Mianserin—Hepatitis—Doxorubicin—ovarian cancer	0.00101	0.00169	CcSEcCtD
Mianserin—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000994	0.00166	CcSEcCtD
Mianserin—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000994	0.00166	CcSEcCtD
Mianserin—Fatigue—Docetaxel—ovarian cancer	0.000992	0.00166	CcSEcCtD
Mianserin—Angiopathy—Epirubicin—ovarian cancer	0.000992	0.00165	CcSEcCtD
Mianserin—Mediastinal disorder—Epirubicin—ovarian cancer	0.000985	0.00164	CcSEcCtD
Mianserin—Constipation—Docetaxel—ovarian cancer	0.000984	0.00164	CcSEcCtD
Mianserin—Asthenia—Paclitaxel—ovarian cancer	0.000974	0.00163	CcSEcCtD
Mianserin—Pruritus—Paclitaxel—ovarian cancer	0.000961	0.0016	CcSEcCtD
Mianserin—Mental disorder—Epirubicin—ovarian cancer	0.000957	0.0016	CcSEcCtD
Mianserin—Feeling abnormal—Docetaxel—ovarian cancer	0.000949	0.00158	CcSEcCtD
Mianserin—Eye disorder—Doxorubicin—ovarian cancer	0.000945	0.00158	CcSEcCtD
Mianserin—Tinnitus—Doxorubicin—ovarian cancer	0.000943	0.00157	CcSEcCtD
Mianserin—Cardiac disorder—Doxorubicin—ovarian cancer	0.000938	0.00157	CcSEcCtD
Mianserin—Angiopathy—Doxorubicin—ovarian cancer	0.000917	0.00153	CcSEcCtD
Mianserin—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000911	0.00152	CcSEcCtD
Mianserin—Dizziness—Paclitaxel—ovarian cancer	0.000898	0.0015	CcSEcCtD
Mianserin—Mental disorder—Doxorubicin—ovarian cancer	0.000886	0.00148	CcSEcCtD
Mianserin—Anaemia—Epirubicin—ovarian cancer	0.000879	0.00147	CcSEcCtD
Mianserin—Agitation—Epirubicin—ovarian cancer	0.000874	0.00146	CcSEcCtD
Mianserin—Rash—Paclitaxel—ovarian cancer	0.000856	0.00143	CcSEcCtD
Mianserin—Dermatitis—Paclitaxel—ovarian cancer	0.000856	0.00143	CcSEcCtD
Mianserin—Vertigo—Epirubicin—ovarian cancer	0.000855	0.00143	CcSEcCtD
Mianserin—Syncope—Epirubicin—ovarian cancer	0.000853	0.00142	CcSEcCtD
Mianserin—Leukopenia—Epirubicin—ovarian cancer	0.000852	0.00142	CcSEcCtD
Mianserin—Headache—Paclitaxel—ovarian cancer	0.000851	0.00142	CcSEcCtD
Mianserin—Loss of consciousness—Epirubicin—ovarian cancer	0.000836	0.00139	CcSEcCtD
Mianserin—Asthenia—Docetaxel—ovarian cancer	0.000826	0.00138	CcSEcCtD
Mianserin—Convulsion—Epirubicin—ovarian cancer	0.000824	0.00137	CcSEcCtD
Mianserin—Hypertension—Epirubicin—ovarian cancer	0.000821	0.00137	CcSEcCtD
Mianserin—Pruritus—Docetaxel—ovarian cancer	0.000814	0.00136	CcSEcCtD
Mianserin—Anaemia—Doxorubicin—ovarian cancer	0.000814	0.00136	CcSEcCtD
Mianserin—Arthralgia—Epirubicin—ovarian cancer	0.00081	0.00135	CcSEcCtD
Mianserin—Myalgia—Epirubicin—ovarian cancer	0.00081	0.00135	CcSEcCtD
Mianserin—Agitation—Doxorubicin—ovarian cancer	0.000809	0.00135	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000804	0.00134	CcSEcCtD
Mianserin—Dry mouth—Epirubicin—ovarian cancer	0.000792	0.00132	CcSEcCtD
Mianserin—Vertigo—Doxorubicin—ovarian cancer	0.000791	0.00132	CcSEcCtD
Mianserin—Syncope—Doxorubicin—ovarian cancer	0.000789	0.00132	CcSEcCtD
Mianserin—Leukopenia—Doxorubicin—ovarian cancer	0.000788	0.00131	CcSEcCtD
Mianserin—Confusional state—Epirubicin—ovarian cancer	0.000783	0.00131	CcSEcCtD
Mianserin—Oedema—Epirubicin—ovarian cancer	0.000776	0.00129	CcSEcCtD
Mianserin—Loss of consciousness—Doxorubicin—ovarian cancer	0.000774	0.00129	CcSEcCtD
Mianserin—Shock—Epirubicin—ovarian cancer	0.000764	0.00127	CcSEcCtD
Mianserin—Convulsion—Doxorubicin—ovarian cancer	0.000763	0.00127	CcSEcCtD
Mianserin—Nervous system disorder—Epirubicin—ovarian cancer	0.000761	0.00127	CcSEcCtD
Mianserin—Dizziness—Docetaxel—ovarian cancer	0.000761	0.00127	CcSEcCtD
Mianserin—Thrombocytopenia—Epirubicin—ovarian cancer	0.00076	0.00127	CcSEcCtD
Mianserin—Hypertension—Doxorubicin—ovarian cancer	0.00076	0.00127	CcSEcCtD
Mianserin—Tachycardia—Epirubicin—ovarian cancer	0.000758	0.00126	CcSEcCtD
Mianserin—Skin disorder—Epirubicin—ovarian cancer	0.000754	0.00126	CcSEcCtD
Mianserin—Myalgia—Doxorubicin—ovarian cancer	0.000749	0.00125	CcSEcCtD
Mianserin—Arthralgia—Doxorubicin—ovarian cancer	0.000749	0.00125	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000744	0.00124	CcSEcCtD
Mianserin—Dry mouth—Doxorubicin—ovarian cancer	0.000733	0.00122	CcSEcCtD
Mianserin—Rash—Docetaxel—ovarian cancer	0.000726	0.00121	CcSEcCtD
Mianserin—Hypotension—Epirubicin—ovarian cancer	0.000726	0.00121	CcSEcCtD
Mianserin—Dermatitis—Docetaxel—ovarian cancer	0.000725	0.00121	CcSEcCtD
Mianserin—Confusional state—Doxorubicin—ovarian cancer	0.000724	0.00121	CcSEcCtD
Mianserin—Headache—Docetaxel—ovarian cancer	0.000721	0.0012	CcSEcCtD
Mianserin—Oedema—Doxorubicin—ovarian cancer	0.000718	0.0012	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000707	0.00118	CcSEcCtD
Mianserin—Shock—Doxorubicin—ovarian cancer	0.000707	0.00118	CcSEcCtD
Mianserin—Nervous system disorder—Doxorubicin—ovarian cancer	0.000705	0.00117	CcSEcCtD
Mianserin—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000703	0.00117	CcSEcCtD
Mianserin—Tachycardia—Doxorubicin—ovarian cancer	0.000701	0.00117	CcSEcCtD
Mianserin—Skin disorder—Doxorubicin—ovarian cancer	0.000698	0.00116	CcSEcCtD
Mianserin—Paraesthesia—Epirubicin—ovarian cancer	0.000697	0.00116	CcSEcCtD
Mianserin—Somnolence—Epirubicin—ovarian cancer	0.00069	0.00115	CcSEcCtD
Mianserin—Hypotension—Doxorubicin—ovarian cancer	0.000671	0.00112	CcSEcCtD
Mianserin—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00067	0.00112	CcSEcCtD
Mianserin—Fatigue—Epirubicin—ovarian cancer	0.000669	0.00112	CcSEcCtD
Mianserin—Constipation—Epirubicin—ovarian cancer	0.000664	0.00111	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000655	0.00109	CcSEcCtD
Mianserin—Paraesthesia—Doxorubicin—ovarian cancer	0.000645	0.00108	CcSEcCtD
Mianserin—Feeling abnormal—Epirubicin—ovarian cancer	0.00064	0.00107	CcSEcCtD
Mianserin—Somnolence—Doxorubicin—ovarian cancer	0.000639	0.00107	CcSEcCtD
Mianserin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00062	0.00103	CcSEcCtD
Mianserin—Fatigue—Doxorubicin—ovarian cancer	0.000619	0.00103	CcSEcCtD
Mianserin—Constipation—Doxorubicin—ovarian cancer	0.000614	0.00102	CcSEcCtD
Mianserin—Feeling abnormal—Doxorubicin—ovarian cancer	0.000592	0.000987	CcSEcCtD
Mianserin—Asthenia—Epirubicin—ovarian cancer	0.000557	0.000929	CcSEcCtD
Mianserin—Pruritus—Epirubicin—ovarian cancer	0.000549	0.000916	CcSEcCtD
Mianserin—Asthenia—Doxorubicin—ovarian cancer	0.000515	0.00086	CcSEcCtD
Mianserin—Dizziness—Epirubicin—ovarian cancer	0.000513	0.000856	CcSEcCtD
Mianserin—Pruritus—Doxorubicin—ovarian cancer	0.000508	0.000848	CcSEcCtD
Mianserin—Rash—Epirubicin—ovarian cancer	0.00049	0.000816	CcSEcCtD
Mianserin—Dermatitis—Epirubicin—ovarian cancer	0.000489	0.000816	CcSEcCtD
Mianserin—Headache—Epirubicin—ovarian cancer	0.000486	0.000811	CcSEcCtD
Mianserin—Dizziness—Doxorubicin—ovarian cancer	0.000475	0.000792	CcSEcCtD
Mianserin—Rash—Doxorubicin—ovarian cancer	0.000453	0.000755	CcSEcCtD
Mianserin—Dermatitis—Doxorubicin—ovarian cancer	0.000453	0.000755	CcSEcCtD
Mianserin—Headache—Doxorubicin—ovarian cancer	0.00045	0.000751	CcSEcCtD
Mianserin—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.68e-05	9.82e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.68e-05	9.81e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MTOR—ovarian cancer	1.68e-05	9.79e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	1.68e-05	9.79e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CAV1—ovarian cancer	1.67e-05	9.78e-05	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—AKT1—ovarian cancer	1.67e-05	9.78e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	1.67e-05	9.76e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—ERBB2—ovarian cancer	1.67e-05	9.74e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	1.67e-05	9.73e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MMP9—ovarian cancer	1.66e-05	9.69e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	1.65e-05	9.65e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	1.65e-05	9.65e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—EGFR—ovarian cancer	1.65e-05	9.65e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MMP9—ovarian cancer	1.65e-05	9.64e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PTEN—ovarian cancer	1.65e-05	9.63e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MTOR—ovarian cancer	1.65e-05	9.63e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	1.65e-05	9.63e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	1.64e-05	9.61e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MTOR—ovarian cancer	1.64e-05	9.61e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PTEN—ovarian cancer	1.64e-05	9.58e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	1.64e-05	9.56e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK3—ovarian cancer	1.62e-05	9.44e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CXCL8—ovarian cancer	1.61e-05	9.4e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	1.61e-05	9.4e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	1.6e-05	9.37e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	1.6e-05	9.35e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—HRAS—ovarian cancer	1.6e-05	9.34e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	1.6e-05	9.32e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—PIK3CA—ovarian cancer	1.59e-05	9.31e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	1.58e-05	9.25e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CXCL8—ovarian cancer	1.58e-05	9.23e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	1.57e-05	9.19e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MYC—ovarian cancer	1.57e-05	9.18e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	1.57e-05	9.18e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	1.57e-05	9.18e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—HRAS—ovarian cancer	1.57e-05	9.17e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—PIK3CA—ovarian cancer	1.57e-05	9.17e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—ovarian cancer	1.56e-05	9.12e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	1.56e-05	9.11e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	1.56e-05	9.09e-05	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	1.56e-05	9.08e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTEN—ovarian cancer	1.55e-05	9.05e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	1.55e-05	9.04e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	1.55e-05	9.04e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	1.54e-05	9.02e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	1.54e-05	9.01e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—ovarian cancer	1.54e-05	9.01e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CASP3—ovarian cancer	1.54e-05	9e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL2—ovarian cancer	1.54e-05	8.99e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK1—ovarian cancer	1.54e-05	8.98e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—EGFR—ovarian cancer	1.54e-05	8.98e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—IL6—ovarian cancer	1.53e-05	8.94e-05	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	1.53e-05	8.94e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	1.53e-05	8.92e-05	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	1.53e-05	8.92e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.53e-05	8.91e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	1.52e-05	8.9e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—ovarian cancer	1.52e-05	8.88e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	1.52e-05	8.88e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—ovarian cancer	1.52e-05	8.87e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CASP3—ovarian cancer	1.52e-05	8.86e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL2—ovarian cancer	1.51e-05	8.84e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CASP3—ovarian cancer	1.51e-05	8.84e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL2—ovarian cancer	1.51e-05	8.82e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—ovarian cancer	1.51e-05	8.81e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—IL6—ovarian cancer	1.51e-05	8.8e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—IL6—ovarian cancer	1.5e-05	8.78e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.5e-05	8.76e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	1.5e-05	8.76e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	1.5e-05	8.76e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.49e-05	8.7e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	1.49e-05	8.7e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.49e-05	8.68e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.48e-05	8.65e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCND1—ovarian cancer	1.48e-05	8.62e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—HRAS—ovarian cancer	1.48e-05	8.62e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—STAT3—ovarian cancer	1.47e-05	8.61e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.47e-05	8.6e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NRAS—ovarian cancer	1.47e-05	8.59e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.47e-05	8.57e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.46e-05	8.55e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.46e-05	8.54e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	1.46e-05	8.52e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.46e-05	8.52e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.46e-05	8.51e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—HRAS—ovarian cancer	1.45e-05	8.49e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTEN—ovarian cancer	1.45e-05	8.49e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.45e-05	8.49e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—HRAS—ovarian cancer	1.45e-05	8.48e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.45e-05	8.46e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—HRAS—ovarian cancer	1.44e-05	8.43e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	1.44e-05	8.42e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	1.44e-05	8.42e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	1.43e-05	8.38e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.43e-05	8.37e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	1.43e-05	8.36e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.43e-05	8.35e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	1.43e-05	8.33e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.42e-05	8.32e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	1.42e-05	8.31e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.42e-05	8.3e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MYC—ovarian cancer	1.42e-05	8.29e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CAV1—ovarian cancer	1.42e-05	8.29e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.41e-05	8.25e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—IL6—ovarian cancer	1.41e-05	8.25e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	1.41e-05	8.23e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.41e-05	8.22e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.4e-05	8.19e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.39e-05	8.13e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—IL6—ovarian cancer	1.39e-05	8.13e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—IL6—ovarian cancer	1.39e-05	8.12e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.39e-05	8.12e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	1.39e-05	8.11e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	1.39e-05	8.11e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—ovarian cancer	1.39e-05	8.1e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.39e-05	8.1e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.38e-05	8.08e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—IL6—ovarian cancer	1.38e-05	8.07e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	1.38e-05	8.06e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL2—ovarian cancer	1.38e-05	8.04e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	1.37e-05	8e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MYC—ovarian cancer	1.37e-05	8e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	1.36e-05	7.96e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.36e-05	7.96e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—TYMS—ovarian cancer	1.36e-05	7.94e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.36e-05	7.92e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PIK3CA—ovarian cancer	1.35e-05	7.86e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.34e-05	7.84e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.34e-05	7.83e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	1.34e-05	7.83e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EGFR—ovarian cancer	1.34e-05	7.83e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.33e-05	7.8e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.33e-05	7.79e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.33e-05	7.79e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.33e-05	7.77e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—HRAS—ovarian cancer	1.33e-05	7.75e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MYC—ovarian cancer	1.33e-05	7.74e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	1.31e-05	7.66e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.31e-05	7.64e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.3e-05	7.61e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—AKT1—ovarian cancer	1.3e-05	7.61e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	1.3e-05	7.58e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	1.3e-05	7.57e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.3e-05	7.57e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.29e-05	7.56e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.29e-05	7.55e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.29e-05	7.54e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—ovarian cancer	1.29e-05	7.54e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.29e-05	7.51e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.28e-05	7.5e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.28e-05	7.5e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—AKT1—ovarian cancer	1.28e-05	7.49e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—AKT1—ovarian cancer	1.27e-05	7.44e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.27e-05	7.44e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.27e-05	7.42e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.27e-05	7.42e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—IL6—ovarian cancer	1.27e-05	7.42e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.27e-05	7.41e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.27e-05	7.39e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.26e-05	7.38e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.26e-05	7.36e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.24e-05	7.22e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—HRAS—ovarian cancer	1.23e-05	7.21e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	1.23e-05	7.16e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.22e-05	7.11e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.21e-05	7.09e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	1.2e-05	7.04e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MYC—ovarian cancer	1.2e-05	7.03e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.18e-05	6.91e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL6—ovarian cancer	1.18e-05	6.9e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MYC—ovarian cancer	1.18e-05	6.9e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.18e-05	6.87e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.18e-05	6.87e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—AKT1—ovarian cancer	1.17e-05	6.84e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.17e-05	6.84e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.17e-05	6.83e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—ovarian cancer	1.17e-05	6.81e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.16e-05	6.79e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.16e-05	6.77e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.16e-05	6.76e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.16e-05	6.76e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.16e-05	6.76e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.16e-05	6.75e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.16e-05	6.75e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.16e-05	6.75e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.14e-05	6.63e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	1.13e-05	6.57e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.13e-05	6.57e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.12e-05	6.54e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	1.11e-05	6.51e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—ovarian cancer	1.11e-05	6.49e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.11e-05	6.47e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—AKT1—ovarian cancer	1.1e-05	6.42e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CAV1—ovarian cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.09e-05	6.39e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—ovarian cancer	1.09e-05	6.37e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—AKT1—ovarian cancer	1.09e-05	6.37e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—ovarian cancer	1.09e-05	6.36e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.08e-05	6.29e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.08e-05	6.29e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.07e-05	6.25e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL6—ovarian cancer	1.07e-05	6.23e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.05e-05	6.15e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.05e-05	6.15e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	1.04e-05	6.08e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.03e-05	6.02e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PIK3CA—ovarian cancer	1.03e-05	5.99e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.02e-05	5.99e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	1.02e-05	5.97e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTEN—ovarian cancer	1.01e-05	5.9e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1e-05	5.87e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	1e-05	5.86e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CG—ovarian cancer	9.97e-06	5.82e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL6—ovarian cancer	9.97e-06	5.82e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	9.95e-06	5.81e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CB—ovarian cancer	9.9e-06	5.78e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—ovarian cancer	9.88e-06	5.77e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	9.84e-06	5.75e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—ovarian cancer	9.72e-06	5.68e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—ovarian cancer	9.7e-06	5.67e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—AKT1—ovarian cancer	9.5e-06	5.55e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—AKT1—ovarian cancer	9.45e-06	5.52e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—HRAS—ovarian cancer	9.45e-06	5.52e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—HRAS—ovarian cancer	9.3e-06	5.43e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—HRAS—ovarian cancer	9.28e-06	5.42e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	9.19e-06	5.37e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	9.14e-06	5.34e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL6—ovarian cancer	9.04e-06	5.28e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—AKT1—ovarian cancer	8.93e-06	5.22e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL6—ovarian cancer	8.9e-06	5.2e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL6—ovarian cancer	8.88e-06	5.19e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—ovarian cancer	8.84e-06	5.17e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CD—ovarian cancer	8.77e-06	5.12e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTEN—ovarian cancer	8.56e-06	5e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	8.46e-06	4.94e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—AKT1—ovarian cancer	8.37e-06	4.89e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—AKT1—ovarian cancer	8.34e-06	4.87e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—AKT1—ovarian cancer	8.21e-06	4.79e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—AKT1—ovarian cancer	8.19e-06	4.78e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL6—ovarian cancer	8.1e-06	4.73e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CB—ovarian cancer	7.64e-06	4.46e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	7.47e-06	4.36e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CA—ovarian cancer	7.12e-06	4.16e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTEN—ovarian cancer	6.6e-06	3.86e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CA—ovarian cancer	6.04e-06	3.53e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—AKT1—ovarian cancer	5.82e-06	3.4e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—AKT1—ovarian cancer	4.93e-06	2.88e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.66e-06	2.72e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—AKT1—ovarian cancer	3.81e-06	2.22e-05	CbGpPWpGaD
